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Letter to the Editor
Excellent reliability of the ALSFRS-R administered via videoconferencing: A study of people with
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Dear Editor,
Introduction
Motor neuron disease is characterised by progressive weakness and
disability, meaning that travel to specialist MND care and research
participation can quickly become difficult. Many pwMND, particularly
those living in remote areas, face troublesome commutes to access care
and to participate in research. Travel-related restrictions have been
shown to impact on attrition in clinical trials [1] and are likely to
contribute to drop-out of clinic-based assessment.
By improving accessibility, reducing costs and mitigating geo-
graphical distances, videoconferencing has the potential to improve
clinical care for pwMND, increase retention in clinical trials and capture
a more diverse cohort of pwMND [2].
Our aim is to enhance the incorporation of telehealth in research
and clinical care by demonstrating that the amyotrophic lateral
sclerosis functional rating scale (ALSFRS-R), a frequently used clinical
instrument, can be reliably administered using videoconferencing. We
also hope to show that videoconferencing has additional advantages
over telephone-based assessments; for example, facilitating non-verbal
communication and supporting pwMND with bulbar impairment to
communicate remotely by typing free text. The ALSFRS-R can be re-
liably administered face-to-face or via telephone [3,4] but administra-
tion via videoconferencing has not been investigated.
We completed a service evaluation to determine the reliability of
videoconferencing-based administration of the ALSFRS-R by comparing
it to face-to-face administration. To distinguish between inter-rater and
inter-method reliability, we assessed inter-rater reliability separately by
comparing ALSFRS-R scores between videoconferencing assessments by
different raters.
Methods
We recruited a convenience sample of pwMND between August
2018 and August 2019, residing in mainland Scotland and remote is-
lands, with a range of disability. Participants were recruited from the
Scottish MND register, the Clinical Audit Research and Evaluation of
MND (CARE-MND) platform. One group of participants completed as-
sessments with the ALSFRS-R via face-to-face appointments and vi-
deoconferencing (n = 20) and another group completed videoconfer-
encing assessments scored by two independent raters (n = 20); two
participants underwent both. Face-to-face and videoconferencing ad-
ministration of the ALSFRS-R occurred within a 15-day period and were
performed by different raters. Raters used the European Network to
Cure ALS (ENCALS) standards for administration [5]. Videoconferen-
cing was undertaken via the NHS Attend Anywhere platform (atten-
danywhere®), which is approved for use by NHS Scotland. Participants
views on the use of videoconferencing were also ascertained in a subset
of participants (n = 20).
Statistical analysis
Internal consistency of ALSFRS-R was determined using Cronbach's
coefficient alpha. Inter-rater and inter-method reliability were assessed
using a two-way random effects model with single measures for abso-
lute agreement (ICC) and graphically displayed using a Bland-Altman
plot. The minimal detectable change (MDC) was calculated as follows:
MDC = 1.96 × SD × √ (1 − ICC) × √ 2.
Effect measures are displayed with 95% confidence intervals (CIs)
and summary statistics as mean and standard deviation (SD) or median
and interquartile range (IQR). Analysis was undertaken in SPSS (ver-
sion 25).
Results
38 pwMND were included. All had ALS, 81.6% (31/38) were male,
mean age was 62.6 years (SD ± 12.2). 81.6% had spinal onset (31/38)
and 18.4% (7/38), had bulbar onset. The mean ALSFRS-R was 30.6 (SD
13.0, range 0–45).
There was excellent reliability and internal consistency in ALSFRS-R
scores between videoconference and face-to-face administration by two
independent raters (ICC = 0.99, 95%CIs 0.99, 0.99; Cronbach's
alpha = 0.99, Fig. 1). The limits of agreement were ± 3 and the MDC
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was 3.6, that is, the smallest change in ALSFRS-R score that is not due to
chance. Assessments took place within a median of 0 days (IQR 0–6).
The inter-rater reliability and internal consistency between video-
conference administration of ALSFRS-R by two independent raters was
also excellent (ICC = 0.99, 95% CI 0.99, 0.99; Cronbach's
alpha = 0.99).
Two participants utilised Eyegaze® software in conjunction with
their PC and participated in ALSFRS-R scoring by typing responses in
the chat box through the videoconferencing software.
90% (18/20) of pwMND described the set up as simple and 85%
(17/20) rated the call quality as “good” or “excellent”; none felt that
any disruption adversely affected the consultation. Participants posi-
tively commented on the convenience, reduction in travel time and
flexibility of timing and location associated with videoconferencing. All
participants were keen to use videoconferencing for future consulta-
tions although 35% (7/20) wished to continue face-to-face consulta-
tions.
Discussion
Our results support the incorporation of videoconferencing-based
ALSFRS-R assessments into research and clinical practice. By reducing
burden of participation, telehealth facilitates involvement in trials by
pwMND who may not otherwise be able to participate, for example,
those with severe disability and those living remotely. A recent tele-
health versus usual care trial reports that several commonly identified
barriers to research participation, time, fatigue and the impact of re-
search on day-to-day life, were not an issue for the pwMND allocated to
the telehealth group. The investigators recommended telehealth as a
cost-effective and low-burden tool for collection of outcome measures
[2].
In keeping with our findings, previous feasibility studies report that
pwMND have a positive attitude towards videoconferencing and enjoy
working with technology [6]. Moreover, videoconferencing was found to
contribute to a sense of increased enablement amongst pwMND [7]. It
enables local therapists [8] and relatives living separately to attend the
consultation. Compared to telephone consultations, videoconferencing
offers several practical advantages for pwMND: We found that the ability
to type free text improved the ease of communication for pwMND with
bulbar impairment and that people using assistive communication de-
vices were able to use the chat facility in conjunction with their devices.
Alternatively, one might consider a self-administered version of the
ALSFRS-R, which was found to be highly reliable [9].
Despite the multitude of benefits associated with videoconferencing
consultations, participants in this study felt that face-to-face consulta-
tions remain an important part of their care. Others reported that
pwMND did not feel comfortable discussing sensitive topics, such as
end-of-life care, via videoconferencing [8] or commented on the lack of
“touch” [10].
In conclusion, ALSFRS-R administered through videoconferencing is
reliable and has the potential to reduce burden of clinical reviews for
pwMND and increase engagement and retention in clinical trials.
Videoconferencing has additional advantages over telephone-based
assessments by allowing pwMND with bulbar impairment to type free
text. Nonetheless, face-to-face assessment remains an important com-
ponent of clinical care.
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